Virtual screening and toxicology prediction of novel potential non-nucleoside reverse transcriptase inhibitors

Current Bioactive Compounds

Volumn 5, Issue 2, 2009, Pages 128-136

  Namba, Adriana Mieco ^a   Da Silva, Vinicius Barreto ^a   Ramos, Thaís Mitleton Borges ^a   Vermelho, Roberta Bonassa ^a   Baptista, Natália Zanon ^a   Da Silva, Carlos Henrique Tomich De Paula ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

(3 PHENOXYPHENYL)(4 PHENYL 1 PIPERAZINYL)METHANONE; (9 ANTHRACENYLMETHYLENE)HYDRAZIDE 2 PYRIDINECARBOXYLIC ACID; 1 (2,2 DIPHENYLETHYL) 4 (4 FLUOROPHENYL)PIPERAZINE; 1 (DIPHENYLMETHYL) 4 (1 OXO 3 PHENYLPROPYL)PIPERAZINE; 3 BENZOYL N (2,3 DIMETHYLPHENYL) 1H INDOLE 1 ACETAMIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DELAVIRDINE; EFAVIRENZ; ETRAVIRINE; N (2 PHENYLETHYL) N (PHENYLMETHYL) 1 PROPYL 4 PIPERIDINAMINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL RESISTANCE; ARTICLE; BINDING SITE; COMPUTER AIDED DESIGN; DRUG SCREENING; DRUG STRUCTURE; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR MODEL; PHARMACOPHORE; PREDICTION; PRIORITY JOURNAL; SIMULATION; TOXICOLOGY; VIRTUAL REALITY;

EID: 70449725238     PISSN: 15734072     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340709788452028     Document Type: Article

References (45)

1. Barre-Sinoussi, F., Chermann, J.C., Rey, F., Nugeyre, M.T., Chamaret, S., Gruest, J., Dauguet, C., Axler-Blin, C., Vezinet- Brun, F., Rouzioux, C., Rozenbaum, W., Montagnier, L. (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science, 220, 868.
2. Gallo, R.C., Sarin, P.S., Gelmann, E.P., Robert-Guroff, M., Richardson, E., Kalyanaraman, V.S., Mann, D., Sidhu, G.D., Stahl, R.E., Zolla-Pazner, S., Leibowitch, J., Popovic, M. (1983) Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science, 220, 865.
3. (a) World Health Organization. Global HIV prevalence has levelled off. http://www.who.int/mediacentre/news/releases/2007/pr61/ en/index.html.
4. (b) Joint United Nations Programme on HIV/AIDS. 2007 AIDS epidemic update http://www.unaids.org/en/ KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/2007. (accessed June 25, 2008).
5. Götte, M., Li, X., Wainberg, M.A. (1999) HIV-1 reverse transcription: A brief overview focused on structure-function relationships among molecules involved in initiation of the reaction. Arch. Biochem. Biophys., 365, 199. (Pubitemid 29391627)
6. Baltimore, D. (1970) RNA-dependent DNA polymerase in virions of RNA tumour viruses. Nature, 226, 1209.
7. Temin, H., Mizutani, S. (1970) RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature, 226, 1211.
8. Hansen, J., Schulze, T., Mellert, W., Moelling, K. (1988) Identification and characterization of HIV-specific RNase H by monoclonal antibody. EMBO J., 7, 239.
9. Gilboa, E., Mitra, S.W., Goff, S.P., Baltimore, D. (1979) A detailed model of reverse transcription and tests of crucial aspects. Cell, 18, 93. (Pubitemid 10228240)
10. Telesnitsky, A., Goff, S.P. (1993) In Reverse Transcriptase, Skalka, A. M. and Goff, S.P., Eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 49-83.
11. Parniak, M.A., Sluis-Cremer, N. (2000) Inhibitors of HIV-1 reverse transcriptase. Adv. Pharmacol., 49, 67.
12. DiMarzo-Veronese, F., Copeland, T.D., DeVico, A.L., Rahman, R., Oroszlan, S., Gallo, R.C., Sarngadharan, M.G. (1986) Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science, 231, 1289.
13. Lightfoote, M.M., Coligan, J.E., Folks, T.M., Fauci, A.S., Martin, M.A., Venkate-san, S. (1986) Structural characterization of reverse transcriptase and endonuclease polypeptides of the acquired immunodeficiency syndrome retrovirus. J. Virol., 60, 771.
14. Kati, W.M., Johnson, K.A., Jerva, L.F., Anderson, K.S. (1992) Mechanism and fidelity of HIV reverse transcriptase. J. Biol. Chem., 267, 25988.
15. Kohlstaedt, L.A., Wang, J., Friedman, J.M., Rice, P.A., Steitz, T.A. (1992) Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science, 256, 1783.
16. Jacobo-Molina, A., Ding, J., Nanni, G., Clark, A.D. Jr, Lu, X., Tantillo, C., Williams, R.L., Kamer, G., Ferris, A.L., Clark, P., Hizi, A., Hughes, S.H., Arnold, E. (1993) Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc. Nat. Acad. Sci USA, 90, 6320. (Pubitemid 23191507)
17. Nanni, G.R., Ding, J., Jacobo-Molina, A., Hughes, S.H., Arnold, E. (1993) Review of HIV-1 reverse transcriptase three-dimensional structure: Implications for drug design. Perspect. Drug Disc. Design, 1, 129.
18. De Clercq, E. (1998) The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral. Res., 38, 153.
19. Spence, R.A., Kati, W.M., Anderson, K.S., Johnson, K.A. (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science, 267, 988.
20. Ding, J., Das, K., Moereels, H., Koymans, L., Andries, K., Janssen, P.A.J., Hughes, S.H., Arnold, E. (1995) Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat. Struct. Biol., 2, 407.
21. Ren, J., Esnouf, R., Garman, E., Somers, D., Ross, C., Kirby, I., Keeling, J., Darby, G., Jones, Y., Stuart, D., Stammers, D. (1995) High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Struct. Biol., 2, 293.
22. Ren, J., Esnouf, R., Hopkins, A.L., Ross, C., Jones, Y., Stammers, D., Stuart, D. (1995) The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure, 3, 915.
23. Ding, J., Das, K., Tantillo, C., Zhang, W., Clark, A.D., Jesser, S., Lu, X., Hsiou, Y., Jacobo-Molina, A., Andries, K., Pauwels, R., Moereels, H., Koymans, L., Janssen, P.A.J., Smith, R.H., Kroeger, K.M., Michejda, C.J., Hughes, S.H., Arnold, E. (1995) Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 Å resolution. Structure, 3, 365.
24. Novikov, M.S., Ozerov, A.A., Orlova, Yu.A., Buckheit, R.W. (2005) Synthesis and Antiviral Activity of 1-{[2-(Phenoxy)ethoxy] methyl}uracil Derivatives. Chem. Heterocycl. Compd., 41, 625.
25. King, R.W., Klabe, R.M., Reid, C.D., Erickson-Viitanen, S.K. (2002) Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immuno-deficiency virus NNRTIs, NRTIs, or protease inhibitors. Antimicrob. Agents Chemother., 46, 1640.
26. Ludovici, D.W., De Corte, B.L., Kukla, M.J., Ye, H., Ho, C.Y., Lichtenstein, M.A. (2001) Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues. Bioorg. Med. Chem. Lett., 11, 2235. (Pubitemid 32781673)
27. Deeks, S.G. (2001) International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Defic. Syndr., 26 Suppl 1, S25.
28. Richman, D.D., Havlir, D., Corbeil, J., Looney, D., Ignacio, C., Spector, S.A., Sullivan, J. (1994) Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol., 68, 1660. (Pubitemid 24065732)
29. Bacheler, L.T., Anton, E.D., Kudish, P., Baker, D., Bunville, J., Krakowski, K., Bolling, L., Aujay, M., Wang, X.V., Ellis, D., Becker, M.F., Lasut, A.L., George, H.J., Spalding, D.R., Hollis, G., Abremski, K. (2000) Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob. Agents Chemother., 44, 2475. (Pubitemid 30650898)
30. Bacheler, L., Jeffrey, S., Hanna, G., D'Aquila, R., Wallace, L., Logue, K. (2001) Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J. Virol., 75, 4999. (Pubitemid 32448520)
31. Delaugerre, C., Rohban, R., Simon, A., Mouroux, M., Tricot, C., Agher, R., Huraux, J.M., Katlama, C., Calvez, V. (2001) Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J. Med. Virol., 65, 445. (Pubitemid 32959067)
32. Demeter, L.M., Shafer, R.W., Meehan, P.M., Holden-Wiltse, J., Fischl, M. A., Freimuth, W. W., Para, M. F., Reichman, R. C. (2000) Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrob. Agents Chemother., 44, 794. (Pubitemid 30117986)
33. Johnson, V.A., Brun-Vézinet, F., Clotet, B., Kuritzkes, D.R., Pillay, D., Schapiro, J.M., Richman, D.D. (2006) Update of the drug resistance mutations in HIV-1: Fall 2006. Topics HIV Med., 14, 125.
34. DS Visualizer v 2.0.1, Accelrys software Inc, CA, 2007.
35. Verdonk, M.L., Cole, J.C., Hartshorn, M.J., Murray, C.W., Taylor, R.D. (2003) Improved protein-ligand docking using GOLD. Proteins: Struc. Func. Genet., 52, 609.
36. Eldridge, M.D., Murray, C.W., Auton, T.R., Paolini, G.V., Mee, R.P. (1997) Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comp.-Aided Molec. Des., 11, 425.
37. http://www.accelrys.com.
38. Laurie, A.T.R., Jackson, R.M. (2005) Q-SiteFinder: An energy-based method for the prediction of protein-ligand binding sites. Bioinformatics, 21, 1908.
39. Ridings, J.E., Barratt, M.D., Cary, R., Earnshaw, C.G., Eggington, C.E., Ellis, M.K., Judson, P.N., Langowski, J.J., Marchant, C.A., Payne, M.P., Watson, W.P., Yih, T.D. (1996) Computer prediction of possible toxic action from chemical structure: An update on the DEREK system. Toxicol., 106, 267. (Pubitemid 26038295)
40. Inbar, Y., Schneidman-Duhovny, D., Dror, O., Nussinov, R., Wolfson, H.J. In Proc. of RECOMB, vol.3692 of Lecture Notes in Computer Science, pp. 423, Springer Verlag, 2007.
41. Insight II User Guide, version 2005, Accelrys: San Diego, USA, 2005.
42. Arfken, G. In Mathematical Methods for Physicists, 3rd ed. Orlando, FL, 1985.
43. Morse, P.M., Feshbach, H. In Methods of Theoretical Physics, Part I. McGraw-Hill, New York, 1953.
44. Dauber-Osguthorpe, P., Roberts, V.A., Osguthorpe, D.J., Wolff, J., Genest, M., Hagler, A.T. (1988) Structure and energetics of ligand binding to proteins: E. coli dihydrofolate reductase-trimethoprim, a drug-receptor system. Proteins: Struct., Funct. Genet., 4, 31. (Pubitemid 18211791)
45. Bus, J.S., Popp, J.A. (1987) Perspectives on the mechanism of action of the splenic toxicity of aniline and structurally-related compounds. Food Chem. Toxicol., 25, 619.